General MedicationsORALGeneric
IRBESARTAN; HYDROCHLOROTHIAZIDE
IRBESARTAN; HYDROCHLOROTHIAZIDE
Standard Dose
150MG; 12.5MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: None (Tentative Approval)
Summary
Approval overview IRBESARTAN; HYDROCHLOROTHIAZIDE is listed in Drugs@FDA under application 090815 (ANDA).
Marketing status: None (Tentative Approval) Active ingredient IRBESARTAN; HYDROCHLOROTHIAZIDE Form and strength TABLET; ORAL - 150MG; 12.5MG Sponsor ZYDUS PHARMS USA INC Submission history Latest submission status date: 2011-02-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview IRBESARTAN; HYDROCHLOROTHIAZIDE is listed in Drugs@FDA under application 090815 (ANDA). Marketing status: None (Tentative Approval) Active ingredient IRBESARTAN; HYDROCHLOROTHIAZIDE Form and strength TABLET; ORAL - 150MG; 12.5MG Sponsor ZYDUS PHARMS USA INC Submission history Latest submission status date: 2011-02-16 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
Interaction Notes
- No interaction notes stored yet.